New drug targets HER2 cancers in major trial

NCT ID NCT07192068

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 34 times

Summary

This study tests a drug called zanidatamab in people with certain advanced cancers (lung, sarcoma, head & neck, colorectal, or endometrial) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. About 105 adults will receive the drug every 3 weeks by IV, and their progress will be tracked with scans. Treatment continues as long as it helps.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Chu Timone
RECRUITING

Marseille, France

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Gustave Roussy
RECRUITING

Villejuif, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut de Cancérologie de Lorraine
ACTIVE_NOT_RECRUITING

Vandœuvre-lès-Nancy, France
Institut de Cancérologie de l'Ouest
ACTIVE_NOT_RECRUITING

Angers, France

Conditions

Explore the condition pages connected to this study.

COLORECTAL CARCINOMA ENDOMETRIAL ENDOMETRIAL HEAD &AMP; NECK CANCER NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER SARCOMA